Cohen Samuel M
Havlik-Wall Professor of Oncology, Department of Pathology, Microbiology, and Immunology and the Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, United States.
Front Oncol. 2024 May 28;14:1394584. doi: 10.3389/fonc.2024.1394584. eCollection 2024.
Cancer arises from multiple genetic errors occurring in a single stem cell (clonality). Every time DNA replicates, mistakes occur. Thus, agents can increase the risk of cancer either by directly damaging DNA (DNA-reactive carcinogens) or increasing the number of DNA replications (increased cell proliferation). Increased cell proliferation can be achieved either by direct mitogenesis or cytotoxicity with regenerative proliferation. Human carcinogens have a mode of action of DNA reactivity, immunomodulation (mostly immunosuppression), increased estrogenic activity (mitogenesis), or cytotoxicity and regeneration. By focusing on screening for these four effects utilizing , , and short-term assays, a biologically based screening for human chemical carcinogens can be accomplished with greater predictivity than the traditional 2-year bioassay with considerably less cost, less time, and the use of fewer animals.
癌症源于单个干细胞中发生的多种基因错误(克隆性)。每次DNA复制时都会出现错误。因此,致癌因素可通过直接损伤DNA(DNA反应性致癌物)或增加DNA复制次数(细胞增殖增加)来增加患癌风险。细胞增殖增加可通过直接有丝分裂或细胞毒性与再生性增殖来实现。人类致癌物具有DNA反应性、免疫调节(主要是免疫抑制)、雌激素活性增加(有丝分裂)或细胞毒性与再生等作用模式。通过利用、和短期试验来重点筛查这四种效应,可以实现基于生物学的人类化学致癌物筛查,其预测性比传统的两年生物测定更高,成本更低、时间更短且使用的动物更少。